

CITATION REPORT

List of articles citing

No significant association between dipeptidyl
peptidase-4 inhibitors and adverse outcomes of COVID-19

DOI: 10.12998/wjcc.v8.i22.5576

World Journal of Clinical Cases, 2020, 8, 5576-5588.

Source: <https://exaly.com/paper-pdf/86829223/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
24	Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021 , 12, 2042018821996482	4.5	19
23	Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning. <i>Cell Metabolism</i> , 2021 , 33, 479-498	24.6	77
22	Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) - A systematic review, meta-analysis, and meta-regression. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021 , 15, 777-782	8.9	21
21	Managing diabetes in diabetic patients with COVID: where do we start from?. <i>Acta Diabetologica</i> , 2021 , 58, 1441-1450	3.9	4
20	Lower COVID-19 Mortality in Patients with Type 2 Diabetes Mellitus Taking Dipeptidyl Peptidase-4 Inhibitors: Results from a Turkish Nationwide Study. <i>Diabetes Therapy</i> , 2021 , 12, 2857-2870	3.6	3
19	Diabetes and COVID-19: The past, the present, and the future. <i>Metabolism: Clinical and Experimental</i> , 2021 , 121, 154814	12.7	19
18	Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies. <i>Endocrinology and Metabolism</i> , 2021 , 36, 904-908	3.5	5
17	The Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis. <i>Archives of Medical Research</i> , 2021 ,	6.6	10
16	Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis. <i>Frontiers in Endocrinology</i> , 2021 , 12, 708494	5.7	9
15	Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review. <i>Diabetes Therapy</i> , 2021 , 12, 3037-3054	3.6	5
14	Newly-Diagnosed Diabetes and Sustained Hyperglycemia are Associated with Poorer Outcomes in COVID-19 Inpatients Without Pre-Existing Diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021 , 14, 4469-4482	3.4	1
13	Impact of Diabetes on COVID-19 Mortality and Hospital Outcomes, a Global Perspective: An ONTOP Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> ,	1	0
12	The enzymes in COVID-19: A review.. <i>Biochimie</i> , 2022 , 197, 38-38	4.6	1
11	Commentary: Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis.. <i>Frontiers in Endocrinology</i> , 2021 , 12, 825100	5.7	2
10	Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 - A systematic review and meta-analysis.. <i>Primary Care Diabetes</i> , 2021 ,	2.4	2
9	Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists. <i>Diabetes Mellitus</i> , 2022 , 25, 27-49	1.6	6
8	The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 731453	5.6	2

7	Impact of diabetes on COVID-19 mortality and hospital outcomes from a global perspective: An umbrella systematic review and meta-analysis.. <i>Endocrinology, Diabetes and Metabolism</i> , 2022 , e338	2.7	2
6	The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis. <i>Frontiers in Endocrinology</i> , 2022 , 13,	5.7	2
5	Human Cell Organelles in SARS-CoV-2 Infection: An Up-to-Date Overview. <i>Viruses</i> , 2022 , 14, 1092	6.2	1
4	Inhibitors of dipeptidyl-peptidase-4: obvious and probable (literature review). <i>Meditsinskiy Sovet</i> , 2022 , 40-45	0.4	
3	Drug-Disease Severity and Target-Disease Severity Interaction Networks in COVID-19 Patients. 2022 , 14, 1828		0
2	Non-Insulin Novel Antidiabetic Drugs Mechanisms in the Pathogenesis of COVID-19. 2022 , 10, 2624		2
1	Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control. 11, 399-410		1